R.h. Dinel Investment Counsel adds Merck & Co. (MRK) to its portfolio

Merck & Co. (MRK) : R.h. Dinel Investment Counsel added new position in Merck & Co. during the most recent quarter end. The investment management firm now holds 18,690 shares of Merck & Co. which is valued at $1,173,171 , the company said in a statement filed on Oct 7, 2016 with the SEC.Merck & Co. makes up approximately 1.32% of R.h. Dinel Investment Counsel’s portfolio.

Other Hedge Funds, Including , Pure Financial Advisors boosted its stake in MRK in the latest quarter, The investment management firm added 41 additional shares and now holds a total of 19,582 shares of Merck & Co. which is valued at $1,229,162. Merck & Co. makes up approx 0.40% of Pure Financial Advisors’s portfolio.Lenox Wealth Advisors reduced its stake in MRK by selling 131 shares or 3.53% in the most recent quarter. The Hedge Fund company now holds 3,576 shares of MRK which is valued at $224,573. Merck & Co. makes up approx 0.07% of Lenox Wealth Advisors’s portfolio.Stillwater Investment Management reduced its stake in MRK by selling 82 shares or 1.46% in the most recent quarter. The Hedge Fund company now holds 5,521 shares of MRK which is valued at $346,719. Merck & Co. makes up approx 0.19% of Stillwater Investment Management’s portfolio.West Oak Capital reduced its stake in MRK by selling 3 shares or 0.03% in the most recent quarter. The Hedge Fund company now holds 9,720 shares of MRK which is valued at $610,416. Merck & Co. makes up approx 0.42% of West Oak Capital’s portfolio.

Merck & Co. opened for trading at $62.77 and hit $62.99 on the upside on Friday, eventually ending the session at $62.77, with a gain of 0.18% or 0.11 points. The heightened volatility saw the trading volume jump to 1,07,75,249 shares. Company has a market cap of $173,572 M.

On the company’s financial health, Merck & Co. reported $0.93 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $0.91. The company had revenue of $9844.00 million for the quarter, compared to analysts expectations of $9782.80 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.86 EPS.

Many Wall Street Analysts have commented on Merck & Co.. Company shares were Reiterated by Barclays on Sep 9, 2016 to “Overweight”, Firm has raised the Price Target to $ 72 from a previous price target of $66 .Credit Suisse Upgraded Merck & Co. on Aug 8, 2016 to ” Outperform”, Price Target of the shares are set at $73.Company shares were Reiterated by Deutsche Bank on Aug 8, 2016 to “Hold”, Firm has raised the Price Target to $ 59 from a previous price target of $58 .

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.